Page last updated: 2024-12-06
dh 524
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 32048 |
CHEMBL ID | 2106194 |
SCHEMBL ID | 635494 |
MeSH ID | M0055961 |
Synonyms (27)
Synonym |
---|
2-((3,4-dichlorophenoxy)methyl)-2-imidazoline hydrochloride |
fenmetozole hydrochloride [usan] |
1h-imidazole, 2-((3,4-dichlorophenoxy)methyl)-4,5-dihydro-, monohydrochloride |
2-imidazoline, 2-((3,4-dichlorophenoxy)methyl)-, monohydrochloride |
2-((3,4-dichlorophenoxy)methyl)-2-imidazoline monohydrochloride |
dh 524 (pharmaceutical) |
fenmetozole hydrochloride |
fenmetozole hydrochloride (usan) |
D04152 |
23712-05-2 |
fenmetazole |
dh-524 |
2-[(3,4-dichlorophenoxy)methyl]-4,5-dihydro-1h-imidazole hydrochloride |
CHEMBL2106194 |
aiw7il0d0b , |
fenmetozole hcl |
unii-aiw7il0d0b |
2-[(3,4-dichlorophenoxy)methyl]-2-imidazoline monohydrochloride |
fenmetozole hydrochloride [mart.] |
SCHEMBL635494 |
DTXSID40178378 |
Q27273949 |
2-[(3,4-dichlorophenoxy)methyl]-4,5-dihydro-1h-imidazole;hydrochloride |
CS-0086329 |
fenmetozole (hydrochloride) |
HY-105960A |
AKOS040745791 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.14) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |